Literature DB >> 16499281

Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins.

Asim K Debnath1.   

Abstract

Class I viral fusion proteins have an important role in the fusion of viral membranes with host cell membranes, a critical step in the viral life-cycle. These proteins all have similar structural features and form six-helix bundles in their fusogenic form, a general mechanism of action for virus-cell fusion. The successful discovery of peptide-based inhibitors of fusion proteins, in addition to the US Food and Drug Administration approval of one of these inhibitors as an anti-HIV-1 drug, confirmed that the inhibition of six-helix bundle formation is a viable strategy for identifying antiviral drugs. Because peptide-based drugs have several limitations, research has been undertaken to identify potent small-molecule inhibitors of six-helix bundle formation in a variety of viruses, including HIV-1, human respiratory syncytial virus and measles virus. Small-molecule inhibitors that disrupt six-helix bundle formation and prevent viral infection have been identified. This review will focus on the discovery of these small-molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499281

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  6 in total

1.  Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.

Authors:  Laura E Luque; Charles J Russell
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform.

Authors:  Minyoung Park; Hisae Matsuura; Robert A Lamb; Annelise E Barron; Theodore S Jardetzky
Journal:  Anal Biochem       Date:  2010-11-05       Impact factor: 3.365

3.  Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency.

Authors:  Rosemary S Harrison; Nicholas E Shepherd; Huy N Hoang; Gloria Ruiz-Gómez; Timothy A Hill; Russell W Driver; Vishal S Desai; Paul R Young; Giovanni Abbenante; David P Fairlie
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

4.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Authors:  Dirk Roymans; Hendrik L De Bondt; Eric Arnoult; Peggy Geluykens; Tom Gevers; Marcia Van Ginderen; Nick Verheyen; Hidong Kim; Rudy Willebrords; Jean-François Bonfanti; Wouter Bruinzeel; Maxwell D Cummings; Herman van Vlijmen; Koen Andries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 5.  Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.

Authors:  Ajit Monteiro; Karl O A Yu; Mark D Hicar
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

Review 6.  Membrane topology of gp41 and amyloid precursor protein: interfering transmembrane interactions as potential targets for HIV and Alzheimer treatment.

Authors:  Concepción Abad; Luis Martínez-Gil; Silvia Tamborero; Ismael Mingarro
Journal:  Biochim Biophys Acta       Date:  2009-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.